Elizabeth Yeu Lin Sells 4,601 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 4,601 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $73.86, for a total value of $339,829.86. Following the completion of the transaction, the insider owned 18,707 shares of the company’s stock, valued at approximately $1,381,699.02. This represents a 19.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total value of $127,200.00.
• On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total transaction of $430,960.00.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $90.78 on Friday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $91.53. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $3.98 billion, a PE ratio of -83.28 and a beta of 0.54. The firm’s 50 day simple moving average is $66.01 and its 200 day simple moving average is $65.93.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.24). The firm had revenue of $173.91 million during the quarter, compared to the consensus estimate of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. As a group, analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TARS. Mizuho decreased their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Guggenheim cut their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Finally, Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.50.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus completed its acquisition of Alkeus, obtaining worldwide rights to gildeuretinol (ALK-001), an investigational once-daily oral treatment for Stargardt disease. The rare inherited eye disease has no FDA-approved therapy and may affect up to 86,000 people in the United States. Tarsus completes Alkeus acquisition
• Positive Sentiment: ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. The regulatory designations and potential to address a significant unmet need strengthen Tarsus’ pipeline, although topline trial data are not expected until 2029. Alkeus acquisition adds Phase 3 program
• Positive Sentiment: Newly published TEASE-1 results showed that daily gildeuretinol significantly reduced the growth rate of retinal atrophic lesions versus an untreated group and was well tolerated, with no reported delays in dark adaptation or night blindness. TEASE-1 study results
• Neutral Sentiment: The acquisition expands Tarsus beyond its commercial XDEMVY business and supports management’s strategy of building a broader eye-care company. However, the transaction’s financial terms and the ultimate commercial value of ALK-001 were not detailed in the reports.
• Negative Sentiment: Insider Elizabeth Lin reported multiple sales totaling approximately $898,000 across September 1–2 under a pre-arranged Rule 10b5-1 trading plan. While such planned transactions may not reflect current management views, the sales add a modest cautionary signal for investors.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 367.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank increased its position in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC raised its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after buying an additional 468 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after buying an additional 172 shares in the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.